Who owns Kiniksa Pharmaceuticals International, plc (KNSA)? Elite investor 13F holders
4 tracked elite investors reported holding Kiniksa Pharmaceuticals International, plc as of 2026-06-30, including Rubric Capital, D.E. Shaw, Renaissance Technologies LLC, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | KINIKSA PHARMACEUTICALS INTL | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 255787210.00 USD | 3999800.000000 | Shares | add | Original filing |
| D.E. Shaw | KINIKSA PHARMACEUTICALS INTL | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 36435896.00 USD | 569756.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | KINIKSA PHARMACEUTICALS INTL | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 4353524.00 USD | 68077.000000 | Shares | buy | Original filing |
| Gotham Asset Management | KINIKSA PHARMACEUTICALS INTL | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 306896.00 USD | 4799.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.